Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linvoseltamab Versus Daratumumab in High-Risk Smoldering Multiple Myeloma
NCT07393282Phase 3Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- May 2026
- Primary completion
- Jul 2033
- Countries
- 6
01
Overview
A Phase 3 trial of linvoseltamab in smoldering multiple myeloma (SMM), sponsored by Regeneron Pharmaceuticals. Started May 2026; status: recruiting.
02
Drugs
linvoseltamab
03
Conditions
smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on NCT07393282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07393282.